Search results
Showing 4951 to 4965 of 5125 results for technology
'Life changing' treatment approved for people with severe asthma
Omalizumab (Xolair) is now available for NHS patients as an add-on treatment for severe, persistent allergic asthma in adults, adolescents and children, says NICE.
Membership of social groups after retirement 'boosts health and wellbeing'
New research published by BMJ Open suggests that membership of social groups such as book clubs or church groups after retirement is linked with improved health and wellbeing.
NICE draft guidance does not recommend risdiplam for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for public consultation which does not recommend risdiplam (also called Evrysdi and made by Roche) for treating the rare genetic disorder spinal muscular atrophy (SMA).
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
NICE draft guidance does not recommend tucatinib for advanced breast cancer
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
NICE has today (20 August 2021) issued final draft guidance which now recommends sapropterin (also called Kuvan and made by BioMarin) as an option for treating phenylketonuria (PKU) in pregnant women until they give birth as well as for treating the condition in people until they turn 22.
New draft guidance from NICE means thousands of people suffering with severe rheumatoid arthritis will have more medicines to choose from.
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
NICE draft guidance recommends abemaciclib for advanced breast cancer
NICE has today published draft guidance which recommends twice-daily pill abemaciclib (also called Verzenios and made by Eli Lilly) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
NICE draft guidance recommends apalutamide for treating prostate cancer
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults
NICE draft guidance recommends new drug for people with ankylosing spondylitis
New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have access to an innovative new drug.
NICE announces details of health technology evaluation methods review
Following approval at its recent Board meeting NICE has confirmed the details of its review of the methods it uses to develop guidance on drugs, medical devices and diagnostics.
NICE announces more people eligible for nusinersen following review of Managed Access Agreement
NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen (also called Spinraza and made by Biogen) for treating the rare genetic disorder spinal muscular atrophy (SMA).
NICE has announced the appointment of two new directors to key positions in newly formed directorates.